Investment
Features
FeesSafety
Academy
More
Pluang+

TAG Immobilien raises 2026 profit forecast after strong H1 with 11% FFO growth

Company Fundamentals
11 Aug 2026
Seeking Alpha
View Source
Bullish
pluang ai news

TAG Immobilien reported a strong first half of 2026, with Funds From Operations (FFO I) rising 9% to EUR 100.2 million and net income from sales in Poland up 12%. Combined FFO II, including FFO I and Polish sales income, grew 11% year-on-year. Due to these strong results, the company has narrowed its 2026 FFO I guidance to the upper end of the previously announced range, signaling confidence in continued profitability.

More News

Abeona Therapeutics' price target cut to $15 after Q2 revenue miss and operational issues with Zevaskyn therapy.

Abeona Therapeutics' price target cut to $15 after Q2 revenue miss and operational issues with Zevaskyn therapy.

Industrial Alliance Securities lowered Abeona Therapeutics' price target from $20 to $15 following a 14% stock drop after the company reported Q2 revenues of $11.4 million, missing analyst expectations. The company faces operational challenges with i...

Analyst Insights
Bearish
54 minutes ago
Inovio advances DNA medicine pipeline with FDA review of INO-3107 and $18.3M funding secured

Inovio advances DNA medicine pipeline with FDA review of INO-3107 and $18.3M funding secured

Inovio Pharmaceuticals is progressing its DNA medicine pipeline with its lead candidate INO-3107 for Recurrent Respiratory Papillomatosis under FDA accelerated review, targeting a decision by October 30, 2026. The company raised $18.3 million in fund...

Market News
Bullish
1 hour ago
Life360 director Morin Brit sells 15,582 shares for $1 million

Life360 director Morin Brit sells 15,582 shares for $1 million

Morin Brit, a director at Life360, sold 15,582 shares of the company, generating $1 million from the transaction. This sale may indicate a personal financial decision or portfolio adjustment by the director. Investors might watch for any further insi...

Market News
Bearish
1 hour ago
AbCellera's stock jumps after successful menopause drug trial and CFO insider buying.

AbCellera's stock jumps after successful menopause drug trial and CFO insider buying.

AbCellera Biologics announced positive Phase 2 trial results for its experimental menopause drug ABCL635, which significantly reduced hot flash frequency by 83%. The stock surged 33.19% to a 52-week high of $11.32, boosting the company's market cap t...

Market News
Bullish
1 hour ago
TOMI Environmental posts 118% revenue growth and beats EPS estimates despite ongoing losses

TOMI Environmental posts 118% revenue growth and beats EPS estimates despite ongoing losses

TOMI Environmental Solutions reported a 118% year-over-year revenue increase to $2.25 million, surpassing analyst estimates of $1.84 million. The company also beat EPS expectations with a loss of $0.05 per share, better than the anticipated loss of $...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App